Phibro Animal Health Corp (PAHC) stock
Close on Nov 17, 2026Market cap $1.42BP/E 14.4Yield 1.37%
Earnings
Phibro Animal Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Phibro Animal Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q2 FY2027ended Dec 31, 2026 | Feb 3, 2027Expected | – | – | – | – | – |
| Q1 FY2027ended Sep 30, 2026 | Nov 4, 2026after the close | $386.80M | +6.3% | $0.72 | $0.79 | Release |
| Q4 FY2026ended Jun 30, 2026 | Aug 26, 2026during market hours | $396.70M | +4.8% | $0.53 | $0.85 | Release |
| Q3 FY2026ended Mar 31, 2026 | May 6, 2026during market hours | $383.50M | +10.3% | $0.59 | $0.76 | Release |
| Q2 FY2026ended Dec 31, 2025 | Feb 4, 2026during market hours | $373.90M | +20.9% | $0.67 | $0.87 | Release |
| Q1 FY2026ended Sep 30, 2025 | Nov 5, 2025during market hours | $363.90M | +39.7% | $0.65 | $0.73 | Release |
| Q4 FY2025ended Jun 30, 2025 | Aug 27, 2025during market hours | $378.70M | +38.6% | $0.42 | $0.57 | Release |
| Q3 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | $347.80M | +32.1% | $0.51 | $0.63 | Release |
| Q2 FY2025ended Dec 31, 2024 | Feb 5, 2025during market hours | $309.30M | +23.8% | $0.08 | $0.54 | Release |
| Q1 FY2025ended Sep 30, 2024 | Nov 6, 2024during market hours | $260.40M | +12.6% | $0.17 | $0.35 | Release |
| Q4 FY2024ended Jun 30, 2024 | Aug 28, 2024during market hours | $273.20M | +7.1% | $0.02 | $0.41 | Release |
| Q3 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | $263.20M | +7.1% | $0.21 | $0.31 | Release |
| Q2 FY2024ended Dec 31, 2023 | Feb 7, 2024during market hours | $249.90M | +2.2% | $0.03 | $0.33 | Release |
| Q1 FY2024ended Sep 30, 2023 | Nov 8, 2023during market hours | $231.30M | -0.5% | -$0.20 | $0.14 | Release |
| Q4 FY2023ended Jun 30, 2023 | Aug 30, 2023during market hours | $255.00M | -0.1% | $0.28 | $0.38 | Release |
| Q3 FY2023ended Mar 31, 2023 | May 3, 2023during market hours | $245.70M | +2.5% | $0.25 | $0.29 | Release |
| Q2 FY2023ended Dec 31, 2022 | Feb 8, 2023during market hours | $244.60M | +5.1% | $0.18 | $0.34 | Release |
| Q1 FY2023ended Sep 30, 2022 | Nov 9, 2022during market hours | $232.50M | +8.3% | $0.10 | $0.21 | Release |
| Q4 FY2022ended Jun 30, 2022 | Aug 24, 2022during market hours | $255.30M | – | $0.18 | $0.36 | Release |
| Q3 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $239.60M | – | $0.44 | $0.33 | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 9, 2022during market hours | $232.70M | – | $0.43 | $0.37 | Release |
| Q1 FY2022ended Sep 30, 2021 | Nov 2, 2021during market hours | $214.70M | – | $0.16 | $0.25 | Release |
| Q4 FY2021ended Jun 30, 2021 | Aug 25, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | – | Release |
| Q2 FY2021ended Dec 31, 2020 | Feb 3, 2021during market hours | – | – | – | – | Release |
| Q1 FY2021ended Sep 30, 2020 | Nov 4, 2020during market hours | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Phibro Animal Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net salesGAAP | FY2027 | $1.55B – $1.60B | – | New | Nov 4, 2026 |
| Net sales | FY2027 | $1.55B – $1.60B | – | New | Aug 26, 2026 |
| Net sales growth | FY2027 | +4% | – | New | Aug 26, 2026 |
| Adjusted EBITDAnon-GAAP | FY2027 | $258.00M – $268.00M | – | New | Nov 4, 2026 |
| Adjusted EBITDAnon-GAAP | FY2027 | $258.00M – $268.00M | – | New | Aug 26, 2026 |
| Diluted EPSGAAP | FY2027 | $2.98 – $3.22 | – | New | Nov 4, 2026 |
| Diluted EPSGAAP | FY2027 | $2.98 – $3.22 | – | New | Aug 26, 2026 |
| Adjusted diluted EPSnon-GAAP | FY2027 | $3.41 – $3.59 | – | New | Nov 4, 2026 |
| Adjusted diluted EPSnon-GAAP | FY2027 | $3.41 – $3.59 | – | New | Aug 26, 2026 |
| Adjusted diluted EPS growthnon-GAAP | FY2027 | +9% | – | Reaffirmed | Aug 26, 2026 |
| Adjusted EBITDA growthnon-GAAP | FY2027 | +3% | – | New | Aug 26, 2026 |
| Adjusted effective income tax ratenon-GAAP | FY2027 | 20% | – | New | Nov 4, 2026 |
| Adjusted effective income tax ratenon-GAAP | FY2027 | 20% | – | New | Aug 26, 2026 |
| Adjusted net incomenon-GAAP | FY2027 | $140.00M – $147.00M | – | New | Nov 4, 2026 |
| Adjusted net incomenon-GAAP | FY2027 | $140.00M – $147.00M | – | New | Aug 26, 2026 |
| Adjusted net income growthnon-GAAP | FY2027 | +9% | – | Raised | Aug 26, 2026 |
| Diluted EPS growthGAAP | FY2027 | +27% | – | Reaffirmed | Aug 26, 2026 |
| Net incomeGAAP | FY2027 | $122.00M – $132.00M | – | New | Nov 4, 2026 |
| Net incomeGAAP | FY2027 | $122.00M – $132.00M | – | New | Aug 26, 2026 |
| Net income growthGAAP | FY2027 | +27% | – | New | Aug 26, 2026 |
Guidance vs results
The last range Phibro Animal Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2026 | Adjusted diluted EPS | $2.98 – $3.10 | $3.21Σ4Q | Above range |
| FY2026 | EPS (GAAP) | $2.25 – $2.44 | $2.44Σ4Q | Within range |
| FY2026 | Revenue | $1.46B – $1.50B | $1.52BΣ4Q | Above range |
| FY2025 | Adjusted diluted EPS | $1.96 – $2.09 | $2.09Σ4Q | Within range |
| FY2025 | EPS (GAAP) | $0.98 – $1.11 | $1.18Σ4Q | Above range |
| FY2025 | Revenue | $1.26B – $1.29B | $1.30BΣ4Q | Above range |
Guidance history
Every forecast Phibro Animal Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | Adjusted EBITDA | FY2027 | $258.00M – $268.00M | New |
| Nov 4, 2026 | Adjusted diluted EPS | FY2027 | $3.41 – $3.59 | New |
| Nov 4, 2026 | Diluted EPS | FY2027 | $2.98 – $3.22 | New |
| Nov 4, 2026 | Adjusted effective income tax rate | FY2027 | 20% | New |
| Nov 4, 2026 | Net income | FY2027 | $122.00M – $132.00M | New |
| Nov 4, 2026 | Adjusted net income | FY2027 | $140.00M – $147.00M | New |
| Nov 4, 2026 | Net sales | FY2027 | $1.55B – $1.60B | New |
| Aug 26, 2026 | Adjusted EBITDA | FY2027 | $258.00M – $268.00M | New |
| Aug 26, 2026 | Adjusted diluted EPS | FY2027 | $3.41 – $3.59 | New |
| Aug 26, 2026 | Diluted EPS | FY2027 | $2.98 – $3.22 | New |
| Aug 26, 2026 | Adjusted diluted EPS growth | FY2027 | +9% | Reaffirmed |
| Aug 26, 2026 | Adjusted effective income tax rate | FY2027 | 20% | New |
| Aug 26, 2026 | Net income growth | FY2027 | +27% | New |
| Aug 26, 2026 | Diluted EPS growth | FY2027 | +27% | Reaffirmed |
| Aug 26, 2026 | Adjusted EBITDA growth | FY2027 | +3% | New |
| Aug 26, 2026 | Adjusted net income growth | FY2027 | +9% | Raised |
| Aug 26, 2026 | Net income | FY2027 | $122.00M – $132.00M | New |
| Aug 26, 2026 | Adjusted net income | FY2027 | $140.00M – $147.00M | New |
| Aug 26, 2026 | Net sales | FY2027 | $1.55B – $1.60B | New |
| Aug 26, 2026 | Net sales growth | FY2027 | +4% | New |
| May 6, 2026 | Adjusted EBITDA | FY2026 | $247.00M – $255.00M | Raised |
| May 6, 2026 | Adjusted diluted EPS | FY2026 | $2.98 – $3.10 | Raised |
| May 6, 2026 | Diluted EPS | FY2026 | $2.25 – $2.44 | Raised |
| May 6, 2026 | Adjusted net income | FY2026 | $122.00M – $127.00M | Raised |
| May 6, 2026 | Adjusted effective tax rate | FY2026 | 25% | Reaffirmed |
| May 6, 2026 | Net income | FY2026 | $92.00M – $100.00M | Raised |
| May 6, 2026 | Net sales | FY2026 | $1.46B – $1.50B | New |
| Feb 4, 2026 | Adjusted EBITDA | FY2026 | $245.00M – $255.00M | Raised |
| Feb 4, 2026 | Adjusted diluted EPS | FY2026 | $2.93 – $3.10 | Raised |
| Feb 4, 2026 | Diluted EPS | FY2026 | $2.08 – $2.32 | Raised |
| Feb 4, 2026 | Adjusted net income | FY2026 | $120.00M – $127.00M | Raised |
| Feb 4, 2026 | Net income | FY2026 | $85.00M – $95.00M | Raised |
| Feb 4, 2026 | Adjusted effective tax rate | FY2026 | 25% | Reaffirmed |
| Feb 4, 2026 | Net sales | FY2026 | $1.45B – $1.50B | Raised |
| Nov 5, 2025 | Adjusted EBITDA | FY2026 | $230.00M – $240.00M | Raised |
| Nov 5, 2025 | Adjusted diluted EPS | FY2026 | $2.64 – $2.81 | Raised |
| Nov 5, 2025 | Diluted EPS | FY2026 | $1.83 – $2.08 | Raised |
| Nov 5, 2025 | Adjusted effective income tax rate | FY2026 | 25% | Reaffirmed |
| Nov 5, 2025 | Net income | FY2026 | $75.00M – $85.00M | Raised |
| Nov 5, 2025 | Adjusted net income | FY2026 | $108.00M – $115.00M | Raised |
| Nov 5, 2025 | Net sales | FY2026 | $1.43B – $1.48B | Reaffirmed |
| Aug 27, 2025 | Adjusted EBITDA | FY2026 | $225.00M – $235.00M | New |
| Aug 27, 2025 | Adjusted diluted EPS | FY2026 | $2.52 – $2.70 | New |
| Aug 27, 2025 | Diluted EPS | FY2026 | $1.79 – $2.03 | New |
| Aug 27, 2025 | Adjusted effective income tax rate | FY2026 | 25% | New |
| Aug 27, 2025 | Net income | FY2026 | $73.00M – $83.00M | New |
| Aug 27, 2025 | Adjusted net income | FY2026 | $103.00M – $110.00M | New |
| Aug 27, 2025 | Net sales | FY2026 | $1.43B – $1.48B | New |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $177.00M – $183.00M | New |
| May 7, 2025 | Adjusted diluted EPS | FY2025 | $1.96 – $2.09 | New |
| May 7, 2025 | Diluted EPS | FY2025 | $0.98 – $1.11 | New |
| May 7, 2025 | Adjusted net income | FY2025 | $80.00M – $85.00M | New |
| May 7, 2025 | Adjusted effective tax rate | FY2025 | 25% | New |
| May 7, 2025 | Net income | FY2025 | $40.00M – $45.00M | New |
| May 7, 2025 | Net sales | FY2025 | $1.26B – $1.29B | New |
| Feb 5, 2025 | Adjusted EBITDA | FY2025 | $172.00M – $180.00M | Raised |
| Feb 5, 2025 | Adjusted diluted EPS | FY2025 | $1.87 – $2.01 | Raised |
| Feb 5, 2025 | Diluted EPS | FY2025 | $0.96 – $1.11 | Raised |
| Feb 5, 2025 | Adjusted effective tax rate | FY2025 | 25% | Raised |
| Feb 5, 2025 | Net income | FY2025 | $39.00M – $45.00M | Raised |
| Feb 5, 2025 | Adjusted net income | FY2025 | $76.00M – $82.00M | Raised |
| Feb 5, 2025 | Net sales | FY2025 | $1.25B – $1.30B | Raised |
| Nov 6, 2024 | Adjusted EBITDA | FY2025 | $124.00M – $132.00M | Raised |
| Nov 6, 2024 | Adjusted diluted EPS | FY2025 | $1.34 – $1.48 | Raised |
| Nov 6, 2024 | Adjusted EPS impact | FY2025 | $0.25 | Lowered |
| Nov 6, 2024 | Diluted EPS | FY2025 | $0.89 – $1.04 | Raised |
| Nov 6, 2024 | Adjusted effective tax rate | FY2025 | 24% – 26% | Lowered |
| Nov 6, 2024 | Adjusted EBITDA margin | FY2025 | 20% | Lowered |
| Nov 6, 2024 | Net income | FY2025 | $36.00M – $42.00M | Raised |
| Nov 6, 2024 | Adjusted net income | FY2025 | $55.00M – $60.00M | Raised |
| Nov 6, 2024 | Net sales | FY2025 | $1.05B – $1.10B | New |
| Nov 6, 2024 | Net Sales | FY2025 | $200.00M | Lowered |
| Aug 28, 2024 | Adjusted EBITDA | FY2025 | $118.00M – $126.00M | New |
| Aug 28, 2024 | Adjusted diluted EPS | FY2025 | $1.22 – $1.37 | New |
| Aug 28, 2024 | Diluted EPS | FY2025 | $0.79 – $0.93 | New |
| Aug 28, 2024 | Adjusted effective income tax rate | FY2025 | 25% – 27% | New |
| Aug 28, 2024 | Net income | FY2025 | $32.00M – $38.00M | New |
| Aug 28, 2024 | Adjusted net income | FY2025 | $50.00M – $56.00M | New |
| Aug 28, 2024 | Net sales | FY2025 | $1.04B – $1.09B | New |
| May 8, 2024 | Adjusted EBITDA | FY2024 | $106.00M – $112.00M | Reaffirmed |
| May 8, 2024 | Adjusted diluted EPS | FY2024 | $1.04 – $1.16 | Reaffirmed |
| May 8, 2024 | Diluted EPS | FY2024 | $0.17 – $0.30 | Lowered |
| May 8, 2024 | Adjusted effective tax rate | FY2024 | 28% – 30% | Reaffirmed |
| May 8, 2024 | Net income | FY2024 | $7.00M – $12.00M | Lowered |
| May 8, 2024 | Adjusted net income | FY2024 | $42.00M – $47.00M | Reaffirmed |
| Feb 7, 2024 | Adjusted EBITDA | FY2024 | $106.00M – $112.00M | Reaffirmed |
| Feb 7, 2024 | Adjusted diluted EPS | FY2024 | $1.04 – $1.16 | Reaffirmed |
| Feb 7, 2024 | Diluted EPS | FY2024 | $0.30 – $0.42 | Lowered |
| Feb 7, 2024 | Adjusted effective tax rate | FY2024 | 28% – 30% | Lowered |
| Feb 7, 2024 | Net income | FY2024 | $12.00M – $17.00M | Lowered |
| Feb 7, 2024 | Adjusted net income | FY2024 | $42.00M – $47.00M | Reaffirmed |
| Nov 8, 2023 | Adjusted EBITDA | FY2024 | $106.00M – $112.00M | Lowered |
| Nov 8, 2023 | Adjusted diluted EPS | FY2024 | $1.04 – $1.16 | Lowered |
| Nov 8, 2023 | Diluted EPS | FY2024 | $0.57 – $0.69 | Lowered |
| Nov 8, 2023 | Adjusted effective tax rate | FY2024 | 31% – 33% | Lowered |
| Nov 8, 2023 | Net income | FY2024 | $23.00M – $28.00M | Lowered |
| Nov 8, 2023 | Adjusted net income | FY2024 | $42.00M – $47.00M | Lowered |
| Aug 30, 2023 | Adjusted EBITDA | FY2024 | $115.00M – $121.00M | New |
| Aug 30, 2023 | Adjusted diluted EPS | FY2024 | $1.12 – $1.27 | New |
| Aug 30, 2023 | Diluted EPS | FY2024 | $0.76 – $0.90 | New |
| Aug 30, 2023 | Adjusted effective tax rate | FY2024 | 33% – 35% | New |
| Aug 30, 2023 | Net income | FY2024 | $31.00M – $36.00M | New |
| Aug 30, 2023 | Adjusted net income | FY2024 | $45.00M – $51.00M | New |
| Aug 30, 2023 | Net sales | FY2024 | $1.00B – $1.05B | New |
| May 3, 2023 | Adjusted EBITDA | FY2023 | $113.00M – $118.00M | Reaffirmed |
| May 3, 2023 | Adjusted diluted EPS | FY2023 | $1.21 – $1.31 | Reaffirmed |
| May 3, 2023 | Diluted EPS | FY2023 | $0.84 – $0.94 | Reaffirmed |
| May 3, 2023 | Adjusted effective tax rate | FY2023 | 33% | Reaffirmed |
| May 3, 2023 | Net income | FY2023 | $34.00M – $38.00M | Reaffirmed |
| May 3, 2023 | Adjusted net income | FY2023 | $49.00M – $53.00M | Reaffirmed |
| Feb 8, 2023 | Adjusted EBITDA | FY2023 | $113.00M – $118.00M | Reaffirmed |
| Feb 8, 2023 | Adjusted diluted EPS | FY2023 | $1.21 – $1.31 | Reaffirmed |
| Feb 8, 2023 | Diluted EPS | FY2023 | $0.84 – $0.94 | Lowered |
| Feb 8, 2023 | Adjusted effective tax rate | FY2023 | 33% | Reaffirmed |
| Feb 8, 2023 | Net income | FY2023 | $34.00M – $38.00M | Lowered |
| Feb 8, 2023 | Adjusted net income | FY2023 | $49.00M – $53.00M | Reaffirmed |
| Nov 9, 2022 | Adjusted EBITDA | FY2023 | $113.00M – $118.00M | Reaffirmed |
| Nov 9, 2022 | Adjusted diluted EPS | FY2023 | $1.21 – $1.31 | Lowered |
| Nov 9, 2022 | Diluted EPS | FY2023 | $0.96 – $1.06 | Lowered |
| Nov 9, 2022 | Adjusted net income | FY2023 | $49.00M – $53.00M | Lowered |
| Nov 9, 2022 | Adjusted effective tax rate | FY2023 | 33% | Raised |
| Nov 9, 2022 | Net income | FY2023 | $39.00M – $43.00M | Lowered |
| Aug 24, 2022 | Adjusted EBITDA | FY2023 | $113.00M – $118.00M | New |
| Aug 24, 2022 | Adjusted diluted EPS | FY2023 | $1.28 – $1.38 | New |
| Aug 24, 2022 | Diluted EPS | FY2023 | $1.11 – $1.21 | New |
| Aug 24, 2022 | Adjusted Net Income | FY2023 | $52.00M – $56.00M | New |
| Aug 24, 2022 | Adjusted effective tax rate | FY2023 | 30% | New |
| Aug 24, 2022 | Net income | FY2023 | $45.00M – $49.00M | New |
| May 4, 2022 | Adjusted EBITDA | FY2022 | $110.00M – $114.00M | Reaffirmed |
| May 4, 2022 | Adjusted diluted EPS | FY2022 | $1.30 – $1.39 | Reaffirmed |
| May 4, 2022 | Adjusted effective tax rate | FY2022 | 26% – 27% | Reaffirmed |
| May 4, 2022 | Adjusted Net Income | FY2022 | $52.80M – $56.40M | Reaffirmed |
| May 4, 2022 | Net sales | FY2022 | $930.00M – $950.00M | Raised |
| Feb 9, 2022 | Adjusted EBITDA | FY2022 | $110.00M – $114.00M | Reaffirmed |
| Feb 9, 2022 | Adjusted diluted EPS | FY2022 | $1.30 – $1.39 | Raised |
| Feb 9, 2022 | Adjusted effective tax rate | FY2022 | 26% – 27% | Lowered |
| Feb 9, 2022 | Adjusted Net Income | FY2022 | $52.80M – $56.40M | Raised |
| Feb 9, 2022 | Net sales | FY2022 | $890.00M – $920.00M | Raised |
| Nov 2, 2021 | Adjusted EBITDA | FY2022 | $110.00M – $114.00M | New |
| Nov 2, 2021 | Adjusted diluted EPS | FY2022 | $1.25 – $1.32 | New |
| Nov 2, 2021 | Adjusted effective tax rate | FY2022 | 29% – 31% | New |
| Nov 2, 2021 | Adjusted net income | FY2022 | $50.70M – $53.30M | New |
| Nov 2, 2021 | Net sales | FY2022 | $860.00M – $890.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Phibro Animal Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- News
- Results
- News
- Update
- Results
- News
- Update
- Results
- News
- Results
- News
- Results
See a number that looks wrong?